https://pharminent.com/oncology/oncology-intelligence-digest-may-12-2026/ 2026-05-12T23:29:24Z Pharminent en Oncology Intelligence Digest • May 12 2026 2026-05-12T23:29:20Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-12-2026/ 2026-05-12T23:03:30Z Pharminent en Strategic News Watch • May 12, 2026 2026-05-12T23:03:27Z Blog https://pharminent.com/80501-2/ 2026-05-12T13:06:45Z Pharminent en 2026-05-12T13:06:40Z Blog https://pharminent.com/bms-hengrui-build-13-asset-pipeline-in-15b-onco-immune-deal/ 2026-05-12T16:29:30Z Pharminent en BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal 2026-05-12T12:19:31Z Blog https://pharminent.com/eu-agrees-plan-to-tackle-essential-medicine-shortages/ 2026-05-12T16:29:34Z Pharminent en EU agrees plan to tackle essential medicine shortages 2026-05-12T12:09:07Z Blog https://pharminent.com/bridgebio-stands-up-to-pfizer-in-attr-cm-as-late-stage-data-hint-at-better-survival/ 2026-05-12T16:29:35Z Pharminent en BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival 2026-05-12T11:34:15Z Blog https://pharminent.com/novo-says-high-dose-wegovy-can-cause-28-weight-loss/ 2026-05-12T16:29:37Z Pharminent en Novo says high-dose Wegovy can cause 28% weight loss 2026-05-12T11:01:53Z Blog https://pharminent.com/340b-in-2026-market-shifts-policy-battles-and-what-they-mean-for-stakeholders-new-live-video-webinar/ 2026-05-12T16:29:39Z Pharminent en 340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar) 2026-05-12T10:30:00Z Blog https://pharminent.com/cellular-intelligence-scoops-up-novos-parkinsons-therapy/ 2026-05-12T16:21:17Z Pharminent en Cellular Intelligence scoops up Novo's Parkinson's therapy 2026-05-12T08:37:02Z Blog https://pharminent.com/rare-disease-gene-therapy/rare-disease-gene-therapy-digest-may-11-2026/ 2026-05-11T23:38:08Z Pharminent en Rare Disease & Gene Therapy Digest • May 11, 2026 2026-05-11T23:38:05Z Blog https://pharminent.com/third-circuit-affirms-denial-of-stelara-biosimilar-injunction/ 2026-05-12T16:21:21Z Pharminent en Third Circuit Affirms Denial of Stelara Biosimilar Injunction 2026-05-11T19:27:42Z Blog https://pharminent.com/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid-and-the-medicare-glp-1-bridge/ 2026-05-12T16:21:23Z Pharminent en What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge 2026-05-11T18:12:09Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-may-11-2026/ 2026-05-11T17:11:35Z Pharminent en Strategic News Watch • May 11, 2026 2026-05-11T17:11:32Z Blog https://pharminent.com/partners-bizengri-cleared-by-fda-for-ultra-rare-cancer-days-after-winning-priority-voucher/ 2026-05-11T16:00:22Z Pharminent en Partner's Bizengri cleared by FDA for ultra-rare cancer days after winning priority voucher 2026-05-11T11:23:25Z Blog https://pharminent.com/deal-finally-unlocks-nhs-access-to-itfs-duchenne-drug/ 2026-05-11T16:00:25Z Pharminent en Deal finally unlocks NHS access to ITF's Duchenne drug 2026-05-11T11:17:05Z Blog https://pharminent.com/bms-sotyktu-secures-ec-approval-for-psoriatic-arthritis/ 2026-05-12T16:08:20Z Pharminent en BMS' Sotyktu secures EC approval for psoriatic arthritis 2026-05-11T09:00:48Z Blog https://pharminent.com/bms-sotyktu-secures-ec-approval-for-psoriatic-arthritis-2/ 2026-05-11T16:00:28Z Pharminent en BMS' Sotyktu secures EC approval for psoriatic arthritis 2026-05-11T08:32:52Z Blog https://pharminent.com/pulsesight-reports-positive-phase-1-data-for-pst611-in-dry-amd/ 2026-05-11T16:00:29Z Pharminent en Pulsesight reports positive phase 1 data for PST611 in dry AMD 2026-05-11T07:34:05Z Blog